2 Stocks I’d Avoid at All Costs
Because of the ongoing COVID-19 pandemic, the past few months have been scary for investors. The stock market's volatile movements over this period have been hard to predict, and it is still difficult to know how things will evolve in the short term. However, I remain confident that the market will eventually recover once the crisis subsides. In the long run, the market will continue climbing -- it always does.
Investors who pick the right stocks now -- and who avoid poor businesses -- will be handsomely rewarded. In that spirit, here are two stocks I think investors had better stay away from: Cronos Group (NASDAQ: CRON) and BioXcel Therapeutics (NASDAQ: BTAI).
At first glance, Cronos may look like an attractive stock to buy, and this is for one major reason: The company has a partnership with Altria (NYSE: MO). In December 2018, the tobacco giant announced it would make an investment of 2.4 billion Canadian dollars in Cronos, thereby acquiring a 45% stake in the pot grower; this transaction also included warrants which gave Altria the right to increase its stake to up to 55%. This deal was big for Cronos.
Source Fool.com
